Aspire Biopharma Holdings (ASBP) EBITDA (2024 - 2026)

Aspire Biopharma Holdings (ASBP) has reported EBITDA for 3 consecutive years, with -$2.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA fell 234.82% year-over-year to -$2.7 million in Q2 2026; TTM through Jun 2026 was -$7.3 million, a 57.54% increase from a year earlier, with the FY2025 full-year figure at -$19.4 million, down 1498.13% from the prior year.
• EBITDA was -$2.7 million for Q2 2026 at Aspire Biopharma Holdings, down from -$1.6 million in the prior quarter.
• Over five years, EBITDA peaked at -$215256.0 in Q3 2024 and troughed at -$15.6 million in Q1 2025.
• A 3-year average of -$3.1 million and a median of -$1.4 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA tumbled 432.16% in 2025 and jumped 89.42% in 2026, its largest moves.
• Over 3 years, EBITDA stood at -$667722.0 in 2024, then slumped by 176.98% to -$1.8 million in 2025, then slumped by 44.81% to -$2.7 million in 2026.
• The last three EBITDA figures came in at -$2.7 million (Q2 2026), -$1.6 million (Q1 2026), and -$1.8 million (Q4 2025), per Business Quant data.